Sec Form 4 Filing - Exter Neil @ Revolution Medicines, Inc. - 2020-02-18

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Exter Neil 2. Issuer Name and Ticker or Trading Symbol Revolution Medicines, Inc. [ RVMD] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE 3. Date of Earliest Transaction (MM/DD/YY) 02/18/2020 (Street) REDWOOD CITY, CA94063 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 02/18/2020 C 0 ( 1 ) ( 2 ) A $ 0 0 ( 1 ) ( 3 ) I See Footnote ( 7 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Convertible Preferred Stock ( 4 ) 02/18/2020 C 0 ( 1 ) ( 8 ) ( 4 ) ( 4 ) Common Stock 0 ( 1 ) $ 0 0 I See Footnote ( 7 ) ( 8 ) Series B Convertible Preferred Stock ( 5 ) 02/18/2020 C 0 ( 1 ) ( 9 ) ( 5 ) ( 5 ) Common Stock 0 ( 1 ) $ 0 0 I See Footnote ( 7 ) ( 9 ) Series C Convertible Preferred Stock ( 6 ) 02/18/2020 C 0 ( 1 ) ( 10 ) ( 6 ) ( 6 ) Common Stock 0 ( 1 ) $ 0 0 I See Footnote ( 7 ) ( 10 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Exter Neil C/O REVOLUTION MEDICINES, INC. 700 SAGINAW DRIVE REDWOOD CITY, CA94063 X Signatures /s/ Jack Anders, as Attorney-in-fact for Neil Exter 02/20/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Reflects a 1-for-4.8661 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. ( 2 )Third Rock Ventures II ("TRV II") directly holds 1,909,317 shares of the Issuer's common stock, Third Rock Ventures III, L.P. ("TRV III") directly holds 8,613,025 shares of the Issuer's common stock and Third Rock Ventures IV, L.P. ("TRV IV") directly holds 1,419,900 shares of the Issuer's common stock upon the conversion of the Issuer's Series A convertible preferred stock (the "Series A Preferred"), the Issuer's Series B convertible preferred stock (the "Series B Preferred"), and the Issuer's Series C convertible preferred stock (the "Series C Preferred"). The Reporting Person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. ( 3 )TRV II directly holds 1,909,317 shares, TRV III directly holds 9,024,031 shares and TRV IV directly holds 1,419,900 shares. The Reporting Person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. ( 4 )The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. ( 5 )The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. ( 6 )The Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. ( 7 )The Reporting Person is a partner of each of Third Rock Ventures GP II, L.P., Third Rock Ventures GP III, L.P. and Third Rock Ventures GP IV, L.P. which is the general partner of each of TRV II, TRV III and TRV IV ("the Funds"), respectively. The Reporting Person disclaims beneficial ownership over the shares held by the Funds, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. ( 8 )Prior to the conversion, TRV III directly held 8,220,641 shares of the Series A Preferred on an as converted to common stock basis. TRV IV directly held 1,027,516 shares of the Issuer's Series A Preferred on an as converted to common stock basis. The Reporting Person is a partner of each of Third Rock Ventures GP III, L.P. and Third Rock Ventures GP IV, L.P., which is the general partner of each of TRV III and TRV IV, respectively. The Reporting Person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. ( 9 )Prior to the conversion, TRV III directly held 342,505 shares of the Series B Preferred on an as converted to common stock basis. TRV II directly held 1,909,317 shares of the Issuer's Series B Preferred on an as converted to common stock basis. TRV IV directly held 342,505 shares of the Issuer's Series B Preferred on an as converted to common stock basis. The Reporting Person is a partner of each of Third Rock Ventures GP II, L.P., Third Rock Ventures GP III, L.P. and Third Rock Ventures GP IV, L.P. which is the general partner of each of TRV II, TRV III and TRV IV, respectively. The Reporting Person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. ( 10 )Prior to the conversion, TRV III directly held 49,879 shares of the Series C Preferred on an as converted to common stock basis. TRV IV directly held 49,879 shares of shares of the Issuer's Series C Preferred on an as converted to common stock basis. The Reporting Person is a partner of each of Third Rock Ventures GP III, L.P. and Third Rock Ventures GP IV, L.P., which is the general partner of each of TRV III and TRV IV, respectively. The Reporting Person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.